Cancer Research

Study results of two investigational drugs that target KRAS-driven cancers co-developed by RAS Initiative investigators at the Frederick National Laboratory for Cancer Research (FNL) and now being tested in patients will be presented at the American Association for Cancer Research Annual Meeting April 25-30 at McCormick Place in Chicago.  Both…

The Frederick National Laboratory for Cancer Research together with the Frederick County Chamber of Commerce organizes the quarterly Biotech Connector Speaker Series. This event promotes and supports the Frederick County and surrounding areas’ biotech and bioscience community and provides an inside look at local advances. Please join fellow…

A four-year effort undertaken by the NCI RAS Initiative has come to fruition, revealing a host of new information about a less-studied KRAS variant that plays a key role in cell biology and human cancers. The team, comprising specialists within the RAS Initiative’s hub—Frederick National Laboratory’s Cancer Research Technology Program (CRTP)—…

Many cancer cells–and lung cancers in particular–have an abnormal number of chromosomes, a feature that can help shield them from therapeutic attack. But now scientists are exploring ways to turn the tables and use this abnormality as a weapon against cancer. In a recent example of this, scientists at the Frederick National Laboratory for…

A team from the National Cancer Institute RAS Initiative and collaborators at Lawrence Livermore National Laboratory and BridgeBio TheRas Pharma have made a dual discovery involving the much-studied protein KRAS, identifying a better model and a highly potent anticancer compound. Their findings, the product of a long-term partnership, appear…

The cancer community will come together for a two-day conference designed to celebrate Black contributions in cancer research and to connect future investigators and collaborators, in order to pave the way for the next generation of Black cancer research professionals.  Black in Cancer, a US/UK-based organization and the Frederick National…

The National Cancer Institute Division of Cancer Treatment and Diagnosis appointed the Frederick National Laboratory to build the Integrated Canine Data Commons. The data commons provides a publicly available cloud-based repository of data on spontaneously arising canine cancer to advance research on human cancers by enabling comparative analysis…

A national effort to understand the molecular basis of numerous cancers by analyzing proteins and genes will benefit from greater diversity in patient samples through a new agreement with the Morehouse School of Medicine, a historically Black medical school in Atlanta. MSM joins the National Cancer Institute’s Clinical Proteomic Tumor…

Artificial intelligence has helped researchers uncover potential avenues for better treatment of endometrial cancer, the most common gynecologic malignancy in the developed world and one with a worsening mortality rate, particularly among Blacks and Hispanics. With the aid of deep learning, a type of AI, a large multi-institutional…

A multi-site clinical trial is in progress for lentiviral-vector-based CD33 CAR T-cell treatments for pediatric Acute Myeloid Leukemia (AML). Six sites were approved for this trial sponsored by the National Marrow Donor Program. NCI’s Division of Cancer Treatment and Diagnosis (DCTD) is funding the Biopharmaceutical Development Program to serve as…